Inosine pranobex-derived coordination complexes for self-adjuvant, self-carrier, and self-assembled vaccines in cancer immunotherapy
Bibliographic record
Abstract
No abstract is available for this record. The assistant can identify its topic from the title, but cannot infer the study’s results.
Source: Not provided · Quality: missing
Research context
OpenAlex topics: Adenosine and Purinergic Signaling · Immunotherapy and Immune Responses · Cancer Immunotherapy and Biomarkers
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (38)
Show source-provided references
1. The dynamics of an immunotherapy duo10.1038/s43018-022-00362-5 ↗
2. Nanoengineered coordination polymers boost cancer immunotherapy10.1016/j.mattod.2023.06.001 ↗
3. Targeted cancer immunotherapy: nanoformulation engineering and clinical translation10.1002/advs.202204335 ↗
4. CAR T cell immunotherapy for human cancer10.1126/science.aar6711 ↗
5. Cancer immunotherapy using checkpoint blockade10.1126/science.aar4060 ↗
6. Personalized vaccines for cancer immunotherapy10.1126/science.aar7112 ↗
7. An immunogenic personal neoantigen vaccine for patients with melanoma10.1038/nature22991 ↗
8. Therapeutic vaccines for cancer: an overview of clinical trials10.1038/nrclinonc.2014.111 ↗
9. Tailoring inorganic nanoadjuvants towards next-generation vaccines10.1039/C8CS00028J ↗
10. Immunoengineering: how nanotechnology can enhance cancer immunotherapy10.1016/j.cell.2015.03.037 ↗
11. Biomaterial-assisted targeted modulation of immune cells in cancer treatment10.1038/s41563-018-0147-9 ↗
12. Material aid for vaccines10.1038/s41563-018-0089-2 ↗
13. A facile approach to preparing personalized cancer vaccines using iron-based metal organic framework10.3389/fimmu.2023.1328379 ↗
14. Inosine pranobex: a key player in the game against a wide range of viral infections and non-infectious diseases10.1007/s12325-019-00995-6 ↗
15. The immune restorative effect of isoprinosine administration on the local graft-versus-host reaction of cancer patients10.1016/0090-1229(83)90192-7 ↗
16. Inosine pranobex - a preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy
17. Isoprinosine induces a rapid lympho - mononuclear response in adult participants10.18044/MedInform.201521.80 ↗
18. Efficacy and safety of inosine pranobex in COVID-19 patients: a multicenter phase 3 randomized double-blind, placebo-controlled trial
19. The role of iron homeostasis in remodeling immune function and regulating inflammatory disease10.1016/j.scib.2021.02.010 ↗
20. Iron oxide nanoparticles inhibit tumour growth by inducing pro-inflammatory macrophage polarization in tumour tissues10.1038/nnano.2016.168 ↗
21. Ultrasmall nanoparticles induce ferroptosis in nutrient-deprived cancer cells and suppress tumour growth10.1038/nnano.2016.164 ↗
22. Ferrous versus ferric oral iron formulations for the treatment of iron deficiency: a clinical overview10.1100/2012/846824 ↗
23. A nanoscale metal organic frameworks-based vaccine synergises with PD-1 blockade to potentiate anti-tumour immunity10.1038/s41467-020-17637-z ↗
24. Enhanced antitumor immune responses via a self-assembled carrier-free nanovaccine10.1021/acs.nanolett.1c00648 ↗
25. Antigen epitope-TLR7/8a conjugate as self-assembled carrier-free nanovaccine for personalized immunotherapy10.1016/j.actbio.2022.01.004 ↗
26. Amplifying STING activation by cyclic dinucleotide-manganese particles for local and systemic cancer metalloimmunotherapy10.1038/s41565-021-00962-9 ↗
27. https://go.drugbank.com/drugs/DB13156.
28. Oral administration of cancer vaccines: challenges and future perspectives
29. CCR7 and its ligands: balancing immunity and tolerance10.1038/nri2297 ↗
30. Ubiquitination of CD86 is a key mechanism in regulating antigen presentation by dendritic cells10.4049/jimmunol.1101643 ↗
31. Cross-presentation by dendritic cells10.1038/nri3254 ↗
32. Revisiting the role of CD4+ T cells in cancer immunotherapy - new insights into old paradigms10.1038/s41417-020-0183-x ↗
33. Cytotoxic CD8+ T cells in cancer and cancer immunotherapy10.1038/s41416-020-01048-4 ↗
34. Engineering an effective immune adjuvant by designed control of shape and crystallinity of aluminum oxyhydroxide nanoparticles10.1021/nn404211j ↗
35. Rod-shaped and fluorine-substituted hydroxyapatite free of molecular immunopotentiators stimulates anti-cancer immunity in vivo10.1039/C6CC02848A ↗
36. Rod-scale design strategies for immune-targeted delivery system toward cancer immunotherapy10.1021/acsnano.9b01271 ↗
37. The shape and size of hydroxyapatite particles dictate inflammatory responses following implantation10.1038/s41598-017-03086-0 ↗
38. Virus-like nanostructures for tuning immune response10.1038/srep16728 ↗